Education
About Us
Working with TipRanks
Follow Us
Citius Pharma (CTXR)
:CTXR
Total Valuation
Citius Pharmaceuticals has a market cap or net worth of $19.21M. The enterprise value is $15.80M.
Market Cap$19.21M
Enterprise Value$15.80M
Share Statistics
Citius Pharmaceuticals has 18,472,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,472,190
Owned by Insiders2.65%
Owned by Institutions0.04%
Financial Efficiency
Citius Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -52.56%.
Return on Equity (ROE)-0.56
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-52.56%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee0.00
Profits Per Employee-1.71M
Employee Count23
Asset Turnover0.00
Inventory Turnover0.03
Valuation Ratios
The current PE Ratio of Citius Pharmaceuticals is ―. Citius Pharmaceuticals’s PEG ratio is -0.52.
PE Ratio―
PS Ratio0.00
PB Ratio2.07
Price to Fair Value2.07
Price to FCF-5.15
Price to Operating Cash Flow-0.57
PEG Ratio-0.52
Income Statement
In the last 12 months, Citius Pharmaceuticals had revenue of 0.00 and earned -39.14M in profits. Earnings per share was -5.97.
Revenue0.00
Gross Profit-209.61K
Operating Income-42.00M
Pretax Income-38.85M
Net Income-39.14M
EBITDA-38.64M
Earnings Per Share (EPS)-5.97
Cash Flow
In the last 12 months, operating cash flow was -20.58M and capital expenditures -4.00, giving a free cash flow of -20.58M billion.
Operating Cash Flow-20.58M
Free Cash Flow-20.58M
Free Cash Flow per Share-1.11
Dividends & Yields
Citius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.32
52-Week Price Change-60.31%
50-Day Moving Average1.29
200-Day Moving Average1.23
Relative Strength Index (RSI)40.47
Average Volume (3m)491.59K
Important Dates
Citius Pharmaceuticals upcoming earnings date is Feb 6, 2026, Before Open (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateFeb 6, 2026
Ex-Dividend Date―
Financial Position
Citius Pharmaceuticals as a current ratio of 0.40, with Debt / Equity ratio of 1.36%
Current Ratio0.40
Quick Ratio0.17
Debt to Market Cap0.00
Net Debt to EBITDA0.08
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Citius Pharmaceuticals has paid 576.00K in taxes.
Income Tax576.00K
Effective Tax Rate-0.01
Enterprise Valuation
Citius Pharmaceuticals EV to EBITDA ratio is -3.68, with an EV/FCF ratio of -5.04.
EV to Sales0.00
EV to EBITDA-3.68
EV to Free Cash Flow-5.04
EV to Operating Cash Flow-5.04
Balance Sheet
Citius Pharmaceuticals has $6.09M in cash and marketable securities with $881.65K in debt, giving a net cash position of $5.21M billion.
Cash & Marketable Securities$6.09M
Total Debt$881.65K
Net Cash$5.21M
Net Cash Per Share$0.28
Tangible Book Value Per Share-$2.42
Margins
Gross margin is -132.05%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-132.05%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Citius Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast18.73%